Comparison of the characteristics and renal outcomes of patients with CPI related nephropathy between the current study and the previously published case reports

CaseRenal ManifestationUrine studies/SerologyMalignancyImmunotherapyTherapyResponse
Nephrotic syndrome cases in relation to immune checkpoint agents
Daanen et al. [13]FSGSRCCNivolumabD/C + steroids+MMFRemissionfollowed by relapse
Kitchluet al. [14]MCDHodgkin lymphomaPembrolizumabD/C + steroidsRemission(partial)
Kitchluet al. [14]MCDMelanomaIpilimumabD/C + steroidsRemission
Lin et al. [9]Membranous Nephropathy (PLA2R neg.)MelanomaNivolumabD/C + steroidsRemission(partial)
Current study (#11)Membranous Nephropathy(PLA2R neg.)RCCNivolumabD/C + steroidsRemission
IgA nephropathy cases in relation to immune checkpoint agents
Jung et al. [16]AKI grade 4Cellular crescents with necrosisSub-epithelial desposition.Proteinuria and hematuriaClear cellKidney cancerNivolumabD/C, steroids and RRTRecovery (RRT was d/c after 5 months)
Kishi et al. [15]AKI grade 2Mesangial exp. with no crescents or endocapillary hypercellularitySub nephrotic proteinuria.HematuriaLung SCCNivolumabD/CRemission(Complete)
Current study (#9)AKI grade 2endocapillary hypercellularityNephrotic range proteinuriaPyuria and hematuriaMelanomaNivolumab+ IpilimumabD/C and steroidsRemission followed by relapse
Current study (#10)AKI grade 3No Glomerular proliferative lesions*No proteinuriaNo hematuria+pyuriaMelanomaPembrolizumabD/C and steroids, MMF, and infliximabPartial recovery
Pauci-immune GN cases in relation to immune checkpoint agents
Van den Brom et al. [12]GPA **Dysmorphic erythrocytes and proteinuriaExtra renal: Cutaneous vasculitisStable lung nodule+PR3-ANCAC; normalMalignant MelanomaIpilimumab followed by PembrolizumabCyclosporine and steroidsRemission
Cusnir et al. [10]GPAFocal proliferative GNExtra renal; Cutaneous vasculitissinusitis+PR3-ANCAC; N/AMalignant MelanomaNivolumab+ Ipilimumabsteroids and rituximabNot Stated
Current study (#6)Focal necrotizing pauci-immune glomerulonephritis with no crescentsExtra renal; N/ANegative ANCAC; N/AG3NSCLC (SCC)NivolumabD/C, steroids and rituximabComplete recovery
Current study (#7)Focal segmental pauci-immune necrotizing glomerulonephritisExtra renal; N/A+MPO-ANCAC; normalG3mRCCTremelimumabD/C, steroids, plasmaphresis and rituximabPartial recovery
Current study (#8)Granulomatous necrotizing vasculitisExtra renal; N/ANegative ANCAC3/4 normalUvealMelanomaNivolumab+ IpilimumabD/C, steroids and rituximabComplete recovery
Anti-dsDNA cases in relation to immune checkpoint agents
Fadel et al. [11]AKI with proteinuriaExtramembranous and mesangial deposits (IgG, IgM, C3, C1q)+dsDNAC; normalMetastaticMelanomaIpilimumabD/CPartial renal recoverydsNDA;not detectable
Current study (#2)AKI with proteinuriaATIN with no I.C. deposition GN+dsDNA and RNPBladder cancerNivolumabD/C and steroidsPartial renal recoverydsNDA and RNP;not detectable

FSGS focal segemental glomerulosclerosis, MCD mininmal change disease, D/C immune checkpoint agent was discontinued, Neg Negative, PLA2R anti-phospholipase-A2 receptor, AKI acute kidney injury, I.C immune complex, GN glomerulonephritis, C, complement, Exp. expansion, AKI acute kidney injury, ATIN acute tubulointerstitial nephritis, RRT renal replacement therapy, GPA granulomatosis with polyangiitis, PR3 proteinase 3, ANCA antineutrophil cytoplasmic antibodies, MPO myeloperoxidase, N/A not available, NSCLC non-small cell lung cancer, mRCC metastatic renal cell carcinoma, dsDNA double stranded DNA

*Renal biospy was done 5 weeks post treatment with steroid, MMF and infliximab

**Presumptive diagnosis. Renal Biopsy was not reported